A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 1.95 USD -10.14% Market Closed
Market Cap: 70.6m USD

Armata Pharmaceuticals Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Armata Pharmaceuticals Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Research & Development
-$31.8m
CAGR 3-Years
-10%
CAGR 5-Years
-25%
CAGR 10-Years
-19%
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.4B
CAGR 3-Years
-8%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.7B
CAGR 3-Years
-1%
CAGR 5-Years
9%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.1B
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.8B
CAGR 3-Years
-6%
CAGR 5-Years
-15%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.1B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-14%

Armata Pharmaceuticals Inc
Glance View

Market Cap
70.6m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
1.75 USD
Overvaluation 10%
Intrinsic Value
Price
A

See Also

What is Armata Pharmaceuticals Inc's Research & Development?
Research & Development
-31.8m USD

Based on the financial report for Mar 31, 2025, Armata Pharmaceuticals Inc's Research & Development amounts to -31.8m USD.

What is Armata Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-19%

Over the last year, the Research & Development growth was 1%. The average annual Research & Development growth rates for Armata Pharmaceuticals Inc have been -10% over the past three years , -25% over the past five years , and -19% over the past ten years .

Back to Top